Abiopharma

MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor

Assured Guaranty Guarantees €200 Million of Debt as part of the Refinancing of France’s A28 Toll Road

Financial statements presentation as of 30.06.2026

Register of shareholders, changes and share capital status - exercise of employee warrants

Management and officers – staffing as of 12.8.26

The company’s liability position as of 30.6.26, by maturity dates

Dividend in the amount of 556.3464 agorot per share, record date: 19.8.26, payment 27.8.26

Q2/semi-annual report for 2026

General Announcement: Net Asset Value ("NAV") as of 11 August 2026

General Announcement: ALLOTMENT AND ISSUANCE OF SHARES PURSUANT TO WARRANT EXERCISE